Authors(Years), Country | Cohort description | Detection method, No. of cases | Result RR(95% CI) |
---|---|---|---|
Ohsawa et al. (1999) [95] Japan | 2162 patients with HCV-related chronic hepatitis (1398 men, 834 women), admitted to 3 medical institutions in Osaka between 1957 and 1997; followed from date of diagnosis to 1997 (average follow-up: 5.7 years) | Anti-HCV, [Obs:Exp] B-cell NHL, 4:1.90 | 2.1 (0.57–5.4) Adjusted age and calendar year |
Rabkin et al. (2002) [117] USA | 48,420 gravida, male partners,and offspring from 20,754 pregnancies, recruited from Kaiser Foundation Health Plan (California) between 1959 and 1966 | Anti-HCV or HCVRNA, B-cell NHL 0/57 MM 0/24 HD 0/14 | No HCV+ controls |
Duberg et al. (2005) [96] Sweden | 27,150 HCV-infected persons notified to Swedish Institute for Infectious Disease Control between 1990 and 2000 (19,147 men, 8003 women); | Anti-HCV [Obs:Exp] B-cell NHL 20:10.06 CLL 4:2.07 MM 7:2.89 | 2.0 (1.2–3.1) 1.9 (0.53–4.95) 2.4 (0.97–5.0), Adjusted age, sex, and calendar year |
Amin et al. (2006) [44] New South Wales, Australia | 75,834 HCV monoinfected (without HBV) persons notified to New South Wales Health Department’s Notifiable Diseases Database between 1990 and 2002 (47,903 men, 27,931 women); median age at viral hepatitis notification: 34 years; 10% of cohort estimated to be co-infected with HIV | [Anti-HCV+ or HCV RNA+], NHL 33 FL 6 Diffuse NHL 19 T-cell NHL, 2 MM 7 HD 4 | 0.9 (0.6–1.2) 0.6 (0.3–1.4) 1.1 (0.7–1.7) 1.1 (0.3–-4.2) 0.8 (0.4–1.7) 0.4 (0.2–1.1) Adjusted age, sex, and calendar year |
UlcickasYood et al. (2007) [94] USA | Cohort of 3888 individuals with chronic HBV infection and comparison cohort of 205,203 individuals without HBV infection; | HCV laboratory test, NHL Neg 116 Pos 3 | 1.0 2.4 (0.74–7.5), Chronic HBV infection, sex, race and ethnicity, age, Charlson comorbidity score, median household income, and study site |
Waters et al. (2005) [118] England | 5823 HIV-positive patients at hospital in London, cohort followed since 1996 and seen at regular intervals for clinical assessment; anti-HCV testing introduced in 1998: | Anti-HCV, NHL Neg 56 Pos 7 Not tested 39 | 1.0 0.97 (0.44–2.1) 1.1 (0.71–1.6) |
Franceschi et al. (2006b) [67] Switzerland | Nested case–control study conducted within ongoing cohort study, enrolling people infected with HIV since 1988 from 7 large hospitals in Switzerland; 298 cases of NHL with HCV serology and information on matching criteria occurred through 2004 (246 men, 52 women) | Anti-HCV, NHL Neg 198 Pos 100 | 1.0 1.05 (0.63–1.75) Adjusted centre, gender, age group, CD4+ count, HIV transmission category, and year of enrollment |